Health Condition 1: H36- Retinal disorders in diseases classified elsewhere
Conditions
Interventions
Intervention1: Faricimab: 6 mg intravitreal 4 weekly for 78 weeks
Control Intervention1: aflibercept: 2 mg intravitreal 4 weekly for 78 weeks
Sponsors
Army hospital research and referral Delhi cantt
Eligibility
Inclusion criteria
Inclusion criteria: BCVA LESS THAN 6/6 IN AFFECTED EYE NEOVASCULAR AMD ON OCT MACULA SRF/IRF
Exclusion criteria
Exclusion criteria: History of any form of uvietis History of systemic vasculitis Coexisting ocular or retinal morbidity other than nAMD Any form of central cataract in phakic patients Any posterior capsular opacification or IOL subluxation in pseudophakic patients Pregnancy Systemic contraindications to anti vegf therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| to compare faricimab and aflibercept to treat neovascular age related macular degeneration using differences in mean best visual acuity after six months in two groupsTimepoint: baseline and at the end of 4 weeks then 8 weeks then 12 weeks till 78 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| to determine the number of patients maintaining q12 weeks dosing interval of faricimab at the end of 78 weeks. to determine the risk of adverse drug reactions with faricimab whenn compared with afliberceptTimepoint: baseline, 4 weeks, 8 weeks,12 weeks then 12 weekly till 78 weeks | — |
Countries
India
Contacts
Public ContactSqn Ldr Shailaza Tripathi
Army Hospital Research and Referral Delhi
Outcome results
None listed